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Dietary gluten present in wheat, rye and barley induces several
gastrointestinal disorders, including celiac disease and non-celiac
gluten sensitivity (NCGS). Celiac disease is an immune-based enter-
opathy triggered by ingestion of gluten in genetically susceptible
individuals resulting from the interaction between genetic and
environmental factors. Although gluten has been recognized as the
main environmental trigger of the disease, a speciﬁc role for the in-
testinal microbiota in celiac disease development has been suggested.
NCGS individuals develop adverse reactions after the exposure to
gluten. Due to the similarities in clinical outcomes and the absence
of diagnostic biomarkers, it is challenging to differentiate NCGS from
celiac disease. The aetiology of NCGS remains unknown, although
the involvement of innate immune mechanisms has been suggested.
Since the inﬂuence of intestinal microbiota on immune cell ho-
meostasis and on education of both innate and adaptive immune
system is well known, the role of host-microbe interactions in the
non-celiac gluten sensitivity have been hypothesized.
This review aims to summarize the current knowledge of the
contribution of microbiota to the pathogenesis and/or onset of
celiac disease. In addition, a brief overview of the possible role of
the microbiota components on the NCGS is presented.
© 2016 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).r Ltdonbehalfof EuropeanSociety forClinicalNutrition andMetabolism. This is
e (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Gluten-related disorders are the umbrella term for all conditions related to gluten ingestion, such as
celiac disease and non-celiac gluten sensitivity (NCGS). The prevalence of these diseases has increased
over the past 50 years, being an emerging health problem worldwide. Currently, celiac disease is
considered the most common food intolerance, prevalence being approximately 1e2% of the popu-
lation [1]. In contrast, the prevalence of NCGS has been estimated to be as high as 6% of the general
population, depending on the population studied [2]. The biological basis of gluten induced symptoms
in the absence of celiac disease is unknown but it has been suggested to be related to immune re-
sponses to components of wheat apart from gluten, such as wheat amylase-trypsin inhibitors (ATIs)
and fermentable oligo-, di-, monosaccharides and polyols (FODMAPs) [2,3].
The main genetic component of celiac disease, HLA-DQ2/DQ8 heterodimers, is well-known.
Although these HLA-DQ genes underlie the disorder, only a small percentage of carriers develop the
disease and thus, other genetic and environmental factors must be involved in the onset of celiac
disease. This review aims to summarize the current knowledge of the contribution of microbiota to
pathogenesis and/or onset of CD. In addition, a brief overview of the possible role of the microbiota
components on the development and/or onset of NCGS will be provided.
2. Celiac disease
Celiac disease is an immune-based enteropathy triggered by ingestion of wheat, rye and barley
derived gluten in genetically susceptible individuals. Upon exposure to gluten, inﬂammatory cascade is
induced in the small intestinal mucosa leading to villous atrophy, crypt hyperplasia and increased
numbers of lymphocytes in the lamina propria. Disruption of intestinal villus structure leads to
impaired epithelial barrier function resulting in nutrient malabsorption that may cause severe
symptoms such as anaemia, osteoporosis and, in case of children, to growth retardation. The clinical
picture of the celiac disease is highly variable and individual-speciﬁc. Classical symptoms of celiac
disease include different gastrointestinal symptoms such as abdominal pain and diarrhoea. However,
many CD patients are predominantly symptomatic, showing both gastrointestinal and extra-intestinal
manifestations. In asymptomatic patients the diagnosis is often delayed and thus the small-bowel
mucosal damage may be severe before the celiac disease is suspected. Therefore, early diagnosis of
the disease is crucial for the prevention of persistent villous atrophy predisposing to severe compli-
cations. Celiac disease is a life-long disease that cannot be cured but the symptoms can disappear and
small bowel mucosal damage, intestinal inﬂammation and epithelial integrity are improved by
commitment to a life-long gluten-free diet.
The main genetic predisposition to celiac disease are the human leucocyte antigen (HLA) DQ2 and
DQ8 haplotypes. These HLA-DQ genes account for approximately 40% of the genetic risk of celiac
disease [4]. However, although these genes underlie the disorder, only a small percentage of carriers
develop disease. In addition, the disease concordance in monozygotic twins has been reported to be
only 85% [5]. Thus, other genetic and environmental factors must be involved in the onset of the
disorder (Fig. 1). Recent genomewide association studies have reported additional 39 non-HLA regions
associated with susceptibility to celiac disease development [4]. Interestingly, most of these regions
contain genes with immune related functions, several of which are also involved in shaping the in-
testinal microbiota. In addition, altered expression of non-speciﬁc celiac disease risk-genes affecting
the host-microbe interactions has recently been reported. For instance, a decreased TOLLIP mRNA
levels were observed in untreated celiac patients when compared to healthy controls [6]. TOLLIP is an
intracellular protein that inhibits toll-like receptor signalling and failure to upregulate its transcription
has been suggested to contribute to the chronic inﬂammation in celiac and inﬂammatory bowel dis-
ease patients [6,7]. These results suggest the potential role of disturbed host-microbe interaction in the
pathogenesis of celiac disease.
It is assumed that aberrant microbiota diversity and relative abundances of speciﬁc bacterial taxa
lead to functional imbalance where the mutualistic relationship between the host and his microbes is
disturbed. Deviations in the microbiota community structure has been associated with several local
and systemic diseases, possibly contributing to the pathogenesis and/or clinical manifestation of these
Fig. 1. Factors contributing to the onset of celiac disease. Both genetic and environmental factors contribute to the development of
celiac disease. Of these, HLA-DQ2 and DQ8 as well as dietary gluten play a direct role in the disturbed immune homeostasis and the
subsequent Th1-type immune response required for the disease onset. The other factors either directly or indirectly lead to the
intestinal microbiota dysbiosis, which may also promote the development of celiac disease. HLA, human leucocyte antigen; PRRs,
pattern recognition receptors.
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gested, but the results remain contradictory [6,9]. This inconsistency may possibly be explained by
different techniques used, different sample types analysed (faecal material vs biopsies), patient's age
range (infants, children or adults), small sample size and limited amount of studies performed.2.1. Microbiota in early life and risk of celiac disease
The initial colonization process of the infant gastrointestinal tract forms the basis for the subsequent
microbiota and immune response development, thus having a major inﬂuence on the later life health
and predisposition to the development of several immune-mediated diseases. Life events occurring in
early life and causing disturbances to the developing resident microbiota can lead to long-lasting
dysbiosis with increased amounts or relative abundances of one or more disease associated bacterial
species. Interestingly, a high frequency of infectious episodes as well as antibiotic treatments, known to
affect the intestinal microbiota, have been associated with the onset of celiac disease in genetically
susceptible infants [10,11].
It has been suggested that despite the different life events, also a speciﬁc disease-biased host ge-
notype may select for the ﬁrst gut colonizers and thus contribute to the disease risk (Fig. 1). Several
studies have reported the inﬂuence of genotype of infants at family risk for developing celiac disease
(HLA-DQ2 vs non-HLA-DQ2/8 genotype) on the early life faecal microbiota composition [12e14]. In a
recent study, 1 month old infants with a high genetic risk for celiac disease were observed to have
lower proportion of Actinobacteria and higher proportion of Firmicutes and Proteobacteria than infants
with low genetic risk for disease development [14]. Moreover, HLA-DQ genotype seems to speciﬁcally
inﬂuence the colonization process of Bacteroides species [12]. In particular, an increased Bacteroides
vulgatus prevalence was associated with the genotype of infants at high risk of celiac disease devel-
opment, whereas increased Bacteroides uniformis prevalence was associated with a low genetic risk
[12]. Indeed, the most constant ﬁnding is the higher abundance of Bacteroides spp. in celiac disease
patients [9,15], although a recent prospective study reported a complete lack of the members of
phylum Bacteroidetes in celiac disease predisposed infants [16]. In addition, Bacteroides fragilis has
been associated with an increased risk for celiac disease development in genetically predisposed
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shown to direct the immune system via its ability to direct the development of CD4þ T cells, thus
inducing the differentiation of Th1-lineage [17]. Therefore, it seems likely that increased abundance of
Bacteroides spp. contributes to the Th1 response found in the small intestinal mucosa of celiac disease
patients [6,18]. Furthermore, a study by Sanz et al. [19] reported a reduction in immunoglobulin A (IgA)
-coated Bacteroides spp. in faeces of untreated and treated celiac patients when compared to healthy
controls, suggesting that host defences against this bacterial groups may be reduced in celiac disease,
thus allowing its increased colonization. Immunoglobulin A is the predominant antibody produced by
at mucosal surfaces. Secretory IgA (sIgA) has diverse biological properties such as immune exclusion,
immunomodulation and maintenance of the integrity of mucosal barriers. In addition, it provides the
ﬁrst line of defence against invading pathogens by targeting microbial antigens in the mucosal envi-
ronment. However, the main role of sIgA seems to be the establishment and maintenance of ho-
meostasis with the commensal microbiota [20]. It has been suggested that coating of commensal
bacteria by sIgA may represent a mechanism by which this discrimination between abundant normal
microbiota and rare pathogens are made [20]. Disrupted production of secretory IgA has been
considered a risk factor for the development of gastrointestinal disorders such as celiac disease [21].
IgA is also the most abundant antibody secreted into the breast-milk and the speciﬁcities of these sIgAs
are shaped by maternal microbiota (reviewed in [22]). Breast milk sIgA provides the ﬁrst source of
antibody-mediated immune protection in the intestine of breast-fed neonate [23]. Transfer of these
maternal sIgA to the infant promotes the establishment of regulatory immune system and supports the
mutualistic relationship with the commensal microbiota [23]. In addition, the presence of commensal
microbes is needed for the induction of the endogenous production of IgA, which is slowly started
while the immune system develops [24]. Thus, reduction in intestinal sIgA seems to contribute to
microbiota dysbiosis and pro-inﬂammatory response [24].
Moreover, the reduction of total Gram-positive bacteria population, especially the abundance of
Biﬁdobacterium spp. [9,15] and the increase in the proportions of Gram-negative bacteria such as
Clostridium groups, Prevotella spp, and Escherichia coli [15,18] have been reported in paediatric celiac
disease patients with an active disease. The reduced abundance of biﬁdobacteria may be of interest,
since they have been suggested to alleviate gastrointestinal symptoms of adult celiac patients [25] as
well as to reduce abdominal pain in healthy individuals [26]. Microbiota dysbiosis of paediatric celiac
disease patients have been suggested to be characterized by an increased microbiota diversity [27],
although contradictory ﬁnding has recently been reported in a study utilizing high-throughput
microarray method [18]. Further studies utilizing the high-throughput methods are needed to
comprehensively evaluate the microbiota diversity and species richness associated with celiac disease.2.2. Microbiota in adult celiac disease patients
Although the majority of studies evaluating the microbiota composition associated with celiac
disease have been performedwith paediatric patients, few studies have also assessed the microbiota in
adult CD patients.
Positive seroreactivity against different microbial antigens in celiac disease patients having estab-
lished small-bowel mucosal damage with villous atrophy and crypt hyperplasia have been reported
[28,29]. These serological responses can be detected already in the early stages of the diseases [28],
suggesting that immune responses to commensal microbiota are already present early in the disease
stage and thus may have a role in the pathogenesis of the celiac disease and the development of
mucosal damage.
The role of intestinal microbiota on different clinical manifestations of the disease was demon-
strated in a study by Wacklin et al. [30], where the microbiota composition, structure and diversity
were observed to differ depending on the manifestation of the disease, especially between intestinal
symptoms (gastrointestinal symptoms or anaemia) and extra-intestinal symptoms (dermatitis her-
petiformis). The patients with classical gastrointestinal symptoms had a higher amount of Proteo-
bacteria than patients with other manifestation of the disease, whereas patients with anaemia had the
lowest microbial richness and distinct clustering of duodenal microbiota proﬁles.
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is a gradual process and it has been estimated that the median time needed to achieve a normal villous
height is 3.8 years [31]. However, a signiﬁcant fraction of celiac disease patients suffer from persistent
symptoms despite an adherence to a gluten-free diet and normalized small bowel mucosa [32]. In
some patients, symptoms can be explained by inadvertent gluten intake or the presence of additional
gastrointestinal disease [33]. In many cases the reason for persistent symptoms cannot be explained
[32]. Microbiota dysbiosis observed in untreated celiac patients is not completely restored after
adherence to a gluten-free diet, suggesting that some changes in microbiota are not secondary to the
inﬂammatorymilieu of the active phase of the disease but could play a primary role in predisposition to
celiac disease development [15,34]. Treated celiac disease patients with persistent symptoms have
been reported to have a microbiota dysbiosis, characterized by Proteobacteria-dominating duodenal
microbiota and reduced microbial richness compared to treated patients without symptoms [35].
It has been suggested that the IL17A producing cells play a major role in the pathogenesis of celiac
disease, that both gluten and CD associated bacteria provoke an IL-17A response in the intestinal
mucosa of CD patients and that the magnitude of the adverse IL-17A reaction to gluten is markedly
inﬂuenced by the composition of the resident microbiota and the amount of CD associated bacteria
present [36]. In their study, Sj€oberg et al. [36] used a mixture of CD associated bacteria (ﬁve Prevotella,
one Lachnoanaerobaculum and one Actinomyces isolate) and gluten to challenge the biopsies taken
from untreated and treated CD patients and from clinical controls. At diagnosis, patients with CD were
observed to have highly elevated levels of IL-17A mRNA in their jejunal mucosa. The levels returned to
normal level on a gluten-free diet [36]. The celiac disease associated bacteria analysed in that study
were capable of inducing an IL-17A response on their own, suggesting that this response seen in active
celiac disease could be (in part) directed against the CD -associated bacteria. In addition, these bacteria
determined the magnitude of the IL-17A response (either suppressing or enhancing) depending on
whether the patient had a strong response to gluten digest alone or not. Interestingly, all patients that
showed a suppressed IL-17A response were observed to be born during the Swedish celiac disease
epidemic, whereas children born after the epidemic showed contradictive response.
Homozygosity for non-functional fucosyltransferase 2 (FUT2) gene leads to the absence of ABH
blood groups (FUT2 non-secretor status) in body ﬂuids. Recently, FUT2 non-secretor status has been
associated with the susceptibility to celiac disease in the Finnish population [37]. Moreover, FUT2
secretor status has been shown to be a major determinant for the gut microbiota richness and the
composition of abundant microbiota in healthy individuals [38,39] as well as in Crohn's disease pa-
tients [40]. Interestingly, recovery after the pathogenic infection was slower in FUT2 deﬁcient mice
when compared to FUT2 sufﬁcient controls [41]. These results suggest that fucosylation of intestinal
epithelial cells may be a protective mechanism that maintains the host-microbial interactions, thus
preventing the development of microbiota dysbiosis. For comprehensive conclusions considering the
role of intestinal microbiota in adult celiac disease patients, further studies utilizing high-throughput
analysis are needed.
2.3. Effect of gluten-free diet on microbiota
Currently, the only effective treatment available for celiac disease is a life-long adherence to a
gluten-free diet. Although the diet is effective and safe, it also creates social and economic burdens to
the patients and some reports have shown that intestinal microbiota is also affected [15,42,43].
Microbiota deviations observed in untreated celiac disease patients were only partly restored after
long-term treatment with gluten-free diet. In young children (6e12 years of age), who had followed
gluten-free diet for two years, a higher diversity and a complete rearrangement in Eubacterium species
community as well as changed metabolomics proﬁles were observed [43]. In contrast, the abundances
of E. coli and Staphylococcus were observed to normalize after dietary treatment [15]. Another study
reported slightly different microbiota shifts, including decreased abundance of biﬁdobacteria, lacto-
bacilli, Clostridium lituseburense and Faecalibacterium prausnitzii, whereas proportions of E. coli and
Enterobacteriaceae increased [42]. Majority of these microbiota changes are most likely caused by a
dietary effect, since transition to a gluten-free diet is associated with a reduced intake of complex
polysaccharides. Although a long-term change in dietary habits is required to provoke major shifts in
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bacteria over a short period of time. For example, consumption of inulin or resistant starch increases
the levels of Biﬁdobacterium spp. and Faecalibacterium prausnitzii or Ruminococcus bromii and Eubac-
terium rectale, respectively [8]. These non-digestible carbohydrates are fermented in the colon by its
microbiota to yield energy for microbial growth and end products such as short-chain fatty acids
(SCFAs), mainly acetate, propionate and butyrate. SCFAs have a profound impact on gut health as an
energy source, an inﬂammationmodulator, a vasodilator and part of gut motility andwound healing. In
addition, they are energy substrates for the colonic epithelium (butyrate) and peripheral tissues (ac-
etate and propionate). The patterns of intestinal fermentation and consequently the types and amounts
of SCFAs produced are determined by how much carbohydrate is consumed and the composition of
intestinal microbiota [44]. Further studies are needed to shed light into the role of these host-
microbiome interactions in the pathogenesis of celiac disease and other immune-mediated diseases.
3. Non-celiac gluten sensitivity
The prevalence of NCGS patients is an emerging health problem and it has been estimated to ac-
count over 6% of the general population, depending on the population studied [2]. However, the real
prevalence of NCGS remains obscure. Currently the risk factors for NCGS have not been established,
although the disorder has a tendency to be associated with female gender and young or middle age
[45]. Non-celiac gluten esensitive individuals develop adverse reactions such as gastrointestinal and
extra-intestinal symptoms after exposure to gluten [46]. Typical gastrointestinal symptoms include
abdominal pain, bloating and altered bowel habit, the most often reported extra-intestinal symptoms
being fatigue, headache, joint or bone pain, mood disorders and skin manifestations [2,45]. Due to the
similarities in clinical outcomes and the absence of diagnostic biomarkers, it is challenging to differ-
entiate NCGS from other gluten related disorders. Typically the diagnosis of NCGS is made after the
exclusion of celiac disease and wheat allergy bymeans of negative celiac serology, negative histological
ﬁndings and negative testing for speciﬁc immunoglobulin E (IgE). The diagnosis is further conﬁrmed by
a positive oral gluten challenge after exclusion of gluten from the diet for few weeks. The gluten
challenge should be implemented in a blinded fashion in order to avoid a possible placebo effect
commonly seen in the dietary interventions [2]. However, this approach lacks speciﬁcity and is difﬁcult
to carry out in clinical practise. In addition, the exclusion of irritable bowel syndrome (IBS) should be
considered during the diagnostic process, since gluten may exacerbate the symptoms in these patients
[47]. In contrast, grain-free diet or diet low in FODMAPs have been shown to alleviate the symptoms in
some IBS patients [48].
Although the aetiology of NCGS is unknown, it has been hypothesized that NCGS involves innate
immune mechanisms without any implication of adaptive immune response [49]. This is in contrast to
celiac disease where overexpression of adaptive immunity markers is detected. Previously it has been
shown that NCGS patients have normal intestinal permeability, normal expression of tight junction
proteins claudin-1 and ZO-1 and signiﬁcantly higher expression of claudin-4 when compared to celiac
disease patients [46]. The upregulation of claudin-4 coincidedwith the increased expression of toll-like
receptor (TLR) proteins TLR1, TLR2 and TLR4 and decreased amount of regulatory T cells when
compared to celiac disease patients [46]. Toll-like receptors are molecular pattern recognition re-
ceptors often residing in the epithelial cell surface that recognize microbe-associated molecular pat-
terns (MAMPs). The dynamic host-microbe interaction mediated by these receptors is crucial for the
maintenance of intestinal homeostasis. Moreover, intestinal microbes have been shown to decrease the
intestinal permeability by upregulating the expression of tight junction proteins [50]. Since intestinal
microbiota has an essential role in regulating the antigenmilieu of enterocytes, it may contribute to the
pathogenesis or onset of non-celiac gluten sensitivity. However, its role in the NCGS has not yet been
studied.
4. Conclusion
Several studies have demonstrated an altered intestinal microbiota composition in celiac disease
patients. However, there is still no consensus yet regarding the special microbial species affecting
L. Nylund et al. / Clinical Nutrition Experimental 6 (2016) 17e24 23positively or negatively to the disease process. In addition, human studies tend to be correlative and
thus evidence supporting the causality between speciﬁc bacteria and the pathogenesis of certain
diseases are difﬁcult to obtain. Majority of the studies reporting association of microbiota with celiac
disease have been carried out with paediatric patients, whose microbiota is still developing and prone
to the compositional ﬂuctuation due to the inﬂuence of a variety of environmental factors. Thus,
studies considering the mature, established microbiota of adult patients are warranted. Moreover,
studies including larger sample sizes and utilizing the newest state-of-the-art methods are needed to
comprehensively analyse the role of the intestinal microbiota and its metabolites in both celiac disease
and NCGS.
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